Secondary Malignancies

  • H. J. Deeg


As marrow transplantation has been used more frequently and with greater success, the number of long-term survivors has grown steadily. Consequently, the probability of detecting long-term side effects of marrow transplantation has increased. As described above, patients are usually prepared for transplantation by the administration of high doses of immunosuppressive/cytotoxic agents and TBI given either alone or in combination. Following the transplant procedure, patients go through a period of profound immunoincompetence. In addition, most of them receive immunosuppressive drugs such as methotrexate, cyclo-sporine or, methylprednisolone, in an attempt to prevent or treat GVHD. Cytotoxic agents, ionizing irradiation, and the use of immunosuppressive drugs are known to be associated with an increased risk of developing malignancies. Malignant tumors have been observed in patients given immunosuppressive treatment after renal or cardiac transplantation. Furthermore, a high incidence of malignant lymphomas has been observed in F1 hybrid mice given parental hemo-poietic grafts. Consequently, there has been concern that patients given TBI and marrow grafts might also be at increased risk of developing secondary malignancies. Studies in dogs and rhesus monkeys given allogeneic or autologous marrow grafts have, indeed, shown an increased incidence of malignant tumors as compared to control animals.


Bone Marrow Transplantation Marrow Transplantation Basal Cell Carcinoma Donor Cell Lymphoproliferative Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Boyd CN, Ramberg RC, Thomas ED (1982) The incidence of recurrence of leukemia in donor cells after allogeneic bone marrow transplantation. Leukemia Research 6: 833PubMedCrossRefGoogle Scholar
  2. Deeg HJ, Sanders J, Martin P, Fefer A, Neiman P, Singer J, Storb R, Thomas ED (1984) Secondary malignancies after marrow transplantation. Exp Hematol 12: 660PubMedGoogle Scholar
  3. Fialkow PJ, Thomas ED, Bryant JI, Neiman PE (1971) Leukaemic transformation of engrafted human marrow cells in vivo. The Lancet I: 251CrossRefGoogle Scholar
  4. Marmont A, Frassoni F, Bacigalupo A, Podesta M, Piaggio G, Van Lint MT, Caimo A, de Filippi S (1984) Recurrence of Ph’-positive leukemia in donor cells after marrow transplantation for chronic granulocytic leukemia. 310: 903Google Scholar
  5. Martin PJ, Shulman HM, Schubach WH, Hansen JA, Fefer A, Miller G, Thomas ED (1984) Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Annals of Int Med 101: 310Google Scholar
  6. Minden MD, Messner HA, Belch A (1985) Origin of leukemic relapse after bone marrow transplantation detected by restriction fragment length polymorphism. J Clin Invest 75: 91PubMedCrossRefGoogle Scholar
  7. Schubach WH, Miller G, Thomas ED (1985) Epstein-Barr virus genomes are restricted to secondary neoplastic cells following bone marrow transplantation. Blood 65: 535PubMedGoogle Scholar
  8. Shapiro RS, Pietryga D, Blazar BR, Greenberg J, McClain K, Kersey K, Ramsay NKC, Filipovich AH (1987) B cell lymphoproliferative disorders following bone marrow transplantation. Progress in Bone Marrow Transplantation R. P. Gale and R. Champlin (eds.) Alan R. Liss, Inc., New York, pp. 647Google Scholar
  9. Witherspoon RP, Schubach W, Neiman P, Martin P, Thomas ED (1985) Donor cell leukemia developing six years after marrow grafting for acute leukemia. Blood 65: 1172PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • H. J. Deeg

There are no affiliations available

Personalised recommendations